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Osteoporosis aﬀects all bones, including those of the facial skeleton. To date the facial bones have not drawn much attention due
to the minimal probability of morbid fractures. Hearing and dentition loss due to osteoporosis has been reported. New research
ﬁndingssuggestthatradiologicexaminationofthefacialskeletoncanbeacost-eﬀectiveadjuncttocomplementtheearlydiagnosis
and the follow up of osteoporosis patients. Bone-mass preservation treatments have been associated with osteomyelitis of the
jawbones, a condition commonly described as osteonecrosis of the jaws (ONJ). The facial skeleton, where alimentary tract mucosa
attaches directly to periosteum and teeth which lie in their sockets of alveolar bone, is an area unique for the early detection of
osteoporosisbutalsoforthepreventionoftreatment-associatedcomplications.Wereviewfacialboneinvolvement inpatientswith
osteoporosis and we present data that make the multidisciplinary approach of these patients more appealing for both practitioners
and dentists. With regard to ONJ, a tabular summary with currently available evidence is provided to facilitate multidisciplinary
practice coordination for the treatment of patients receiving bisphosphonates.
1.Introduction
Osteoporosis is a very common medical condition aﬀecting
over 5% of the global population [1, 2]. A considerable
proportionofthesepatientswillsustainoneormorefragility
fractures in their remaining lifetime [1–3]. Despite its low
case fatality, morbidity from osteoporosis poses important
socioeconomic burden [4]. The incidence of osteoporosis
has been known to be on the rise; however, a break in this
trend has been reported in the last decade [5]. Therefore,
osteoporosis is considered as a serious public health concern
which aﬀects both genders [1, 6]. Expectedly, research is
focused in the development of new treatments for osteo-
porosis while a variety of drugs have been made available
during the past 50 years. The treatment of osteoporosis
involves management of osteoporosis-associated fractures,
universal prevention measures, and medical treatment of
the underlying disease. Orthopaedic surgeons deal with
osteoporotic fractures, while the nutrition and exercise are
the leading prevention measures to reduce risk factors for
osteoporosis. Medications are recommended for patients at
high risk of fractures to reduce fractures. Risk factors to be
considered in making the treatment decision include age,
prior history of fracture, family history of fracture, weight,
underlying diseases and medications, bone mineral density,
and current smoking [7]. Currently approved medications
include alendronate (Fosamax), risedronate (Actonel), and
raloxifene (Evista) for prevention and treatment of osteo-
porosis; teriparatide (Forsteo), denosumab (Prolia), zolen-
dronic acid (Aclasta), ibandronate (Bondenza) nasal calci-
tonin spray (Miacalcin) for treatment only, and estrogens or
combinations of hormones (hormone replacement therapy
(HRT)) for prevention only. Osteoporosis is asymptomatic
until a fracture occurs, which poses a major challenge for the
treating physician and may in part explain why relatively few
patients receive a diagnosis of osteoporosis [8]. Bone mineral2 Journal of Osteoporosis
density (BMD) has been reported to correlate for more than
three quartiles of total bone strength [9, 10]. Quantization
of BMD to predict the risk of fractures is of the same order
of importance and eﬃcacy as measuring blood pressure or
cholesterol levels to predict the risk of experiencing stroke or
myocardial infarction [8–10]. Spine and hip BMDsignify the
risks of experiencing vertebral and hip fractures. The gold
standard method for determining BMD is dual energy X-
ray absorptiometry (DXA). Other BMD measures include
peripheral DXA, calcaneal ultrasonography [11] and digital
X-ray radiogrammetry, and they are used to screen for
and to predict the short-term risk of experiencing fracture
[12–14]. The World Health Organization (WHO) deﬁnes
osteoporosis in postmenopausal women as a BMD with
T score over 2.5 standard deviations below the mean for
young healthy adults. A BMD between 1.0 and 2.5 standard
deviations below the mean (T score = −1.0 to −2.5) is
classiﬁed as osteopenia. The risk of fracture is proportionate
to the decrease in BMD. Nonetheless, more fractures are seen
in people with osteopenia than in people with osteoporosis,
because the number of people with osteopenia is higher
[9, 10, 14–16]. Personal risk factors for hip fracture [15, 16]
have been identiﬁed from epidemiologic studies such as the
Study of Osteoporotic Fractures [8, 15].
The facial skeleton is diﬀerent from the remainder of
skeleton; the main diﬀerence is the fact that it comprises
membranousratherthanchondrogenousbones.Bonedevel-
opment occurs in two main forms. The majority of bones is
preformed in cartilage which is later replaced (endochondral
ossiﬁcation, endochondral bone). However, in the skull and
the clavicle, bone forms directly in membranous connective
tissue (intramembranous ossiﬁcation, membranus bone). A
brief look at the history of the skeleton may explain why
[17, 18]. Calciﬁed skeletal tissues replaced silicacious in
the Cambrian period, most probably because physiological
changes either in the beasts or the oceans in which they lived,
allowed retention of Ca ions. It was then those brachiopods,
nautiloids, trilobites gradually converted. Later the ﬁrst
vertebrates had bony scales embedded in their skin—those
aroundthemouthincidentallyformingtheprimitivebasisof
teeth. In some phylogeny lineages, these scales fused to form
bony carapaces [17, 18]. Humans retained these carapaces
over our heads as skull vaults. Later the rest of the skeleton
like the vertebrae, which were cartilaginous also became
bony. This phylogeny explains the distribution and origins
of membrane and cartilaginous bone. Facial bones directly
ossify from mesenchyme. The surviving membranous bones
in the head and part of the clavicle are fragments of
the dermal shield. The formation of membranous bone
from neural crest-derived mesenchyme of the maxillary
and mandibular processes of the embryo depends upon
preceding interactions between the mesenchyme and max-
illary or mandibular epithelia. These epithelial-mesenchyme
interactionsthatinitiateosteogenesisinboththemandibular
and the maxillary processes have been reported to be
permissive interactions [19]. Centres of ossiﬁcation that are
marked by the appearance of calciﬁed matrix appear during
lifetime,someinembryoniclife,othersinfetalandyetothers
well into the postnatal growing period. Some bones ossify
from a single ossiﬁcation centre, others from a group, of
which one is the primary (central and premature) and the
remainder secondary (later and often peripheral) [17]. The
bones in the skull and facial complex remain separated by a
ﬁbrous union (suture) until the seventh or eighth decade of
life [20]. Sutures function as intramembranous bone growth
sites that remain in an unossiﬁed state, to allow new bone
to be formed at the edges of the overlapping bone fronts.
This process relies on the production of suﬃcient new bone
cells which are recruited into the bone fronts, while ensuring
that the cells within the suture remain undiﬀerentiated.
Contrary to endochondral growth plates that can expand
through chondrocyte hypertrophy, sutures do not posses
intrinsic growth potential. Rather, they produce new bone
at the sutural edges of the bone fronts in response to
external stimuli, such as signals arising from the expanding
neurocranium or from facial muscles tension [20].
Phylogeny which was primarily based on observations
is nowadays discovered through molecular sequencing data
and morphological data matrices [18, 21]. Depending on
their membranous or endochondral origin, bones have
distinct signaling properties, which need to be considered in
the research and application of bone biology [22, 23]. This
is not theoretical as clinical implications have already been
reported [24]. In this regard, we review issues related to the
facial skeleton in patients with osteoporosis.
2. Inner Ear Issues in Patients with Osteoporo-
sis
Hearing loss in patients with osteoporosis has long been
described. The majority of reported osteoporotic patients
with hearing loss were aﬀected by Paget disease [25]. The
hormonal control of bone metabolism has taken on a new
dimension since the description, within the last decade, of
a major osteoclast inhibiting control system. The receptor
activator of nuclear factor-[kappa]B (NF-[kappa]B) ligand
(RANKL) produced by osteoblastic lineage cells, binds with
its receptor RANK, located on osteoclasts, in order to
allow the maturation and activation of osteoclasts [26]. The
potential continuous bone loss is controlled by the decoy
receptor osteoprotegerin (OPG) which competitively binds
to RANKL and hence blocks the interaction of RANKL-
RANK [26, 27]. Estrogens contribute to bone protection
sincetheydecreasetheresponseofosteoclaststoRANKLand
induce osteoclast apoptosis. But estrogens, are stimulators
of prolactin release. Prolactin aﬀects calcium metabolism
and pregnancy-induced hyperprolactinemia aﬀects BMD.
Long-term estrogen treatment in guinea pig results in
hyperprolactinemia and has been reported to lead to hearing
loss as well as bone dysmorphology of the otic capsule [28].
Recent data show that prolactin decreases OPG and increases
RANKL [29]. OPG has been shown to be expressed at high
levels in the cochlea and OPG knock-out mice have indeed
abnormal remodeling of the otic capsule and resorption of
the auditory ossicles [30]. This might explain why oral con-
traception treatment and hormone replacement therapies,
involving estrogen together with progestin, increase the riskJournal of Osteoporosis 3
of otosclerosis and vestibular disorders [31]. Benign parox-
ysmal positional vertigo (BPPV), also called canalolithiasis
and cupulolithiasis has been associated with lower T-scores
in postmenopausal women. The diagnosis of osteopenia
or osteoporosis was conﬁrmed by a bone mineral density
measurement made with DXA of spine and hip (T-score)
[32]. These results suggested a possible relationship between
recurrent BPPV and a decreased ﬁxation of calcium in bone
in postmenopausal women. In an experimental model used
to test this hypothesis, in which osteopenia/osteoporosis was
induced by bilateral ovariectomy in female rats, the density
of otoconia was decreased and their size was increased when
compared to the control group. Utricular otoconia of both
groups of ratsexamined by conventional and epiﬂuorescence
microscopy, labeling with calcein showed lack of external
calcium turnover into otoconia of adult female rats [33].
3. Oral Health in Patientswith Osteoporosis
Several other factors also aﬀect the dental management of
this disease. Patients diagnosed with or at high risk for
developing osteoporosis often have other chronic diseases.
These patients’ oral health is also compromised since they
are receiving medications to treat these diseases and due
to physical disability and poor hygiene compliance issues.
They usually have major dental requirements and their
poor oral health can cause systemic health deterioration.
Preserving the natural dentition of those patients promotes
better nutrition and improves appearance [34, 35]. On
the other hand, poor oral health in this population can
contribute to increased morbidity and decreased quality of
life [35–37]. People with chronic diseases and poor oral
health are at increased risk of developing opportunistic
infections such as pneumonia and of xerostomia induced
by medications [35, 36]. Patients’ poor oral hygiene, loss
of hand dexterity, lack of compliance and poor dentition
can, in turn, impair oral function [35, 38]. Therefore,
dental care is indicated for these patients; to provide
satisfactory care, dentists need to understand osteoporosis,
its treatments and its complications. A number of review
articles about osteoporosis and periodontal disease discussed
various issues regarding BMD and oral alveolar bone loss,
premature teeth loss and increased severity of periodontal
disease in patients with osteoporosis [39–41]. Common
risk factors for osteoporosis and periodontal disease include
smoking, old age, and low intake of calcium and vitamin
D[ 8]. Since both osteoporosis and periodontitis are highly
prevalent and markedly associated with aging, studies have
been performed to investigate the association between these
diseases over the past decades [39, 40, 42]. Experimental
results [43] suggest that despite those studies, no clear
association between these diseases exist other than common
risk factors. Through recognizing common risk factors for
both osteoporosis and periodontal disease and performing
clinical and radiographic dental examinations dentists iden-
tify patients who are at risk of developing osteoporosis.
The results of radiographic assessment of the alveolar
trabecular pattern can be a clinical indicator of BMD [44].
Other studies suggest that routine panoramic radiographs
also can be used to detect low BMD, osteoporosis and
risk of experiencing vertebral fracture in postmenopausal
women [45–48]. These studies also showed that providing
special training to dental practitioners on speciﬁc evaluation
techniques and reading panoramic radiographs enhanced
their detection of osteoporosis related radiographic changes.
Brieﬂy, the radiographic examination of the mandibular
inferior cortex can reveal changes that vary from normal
with the endosteal cortical margins being even and sharp
bilaterally,to mild ormoderate erosion of the inferior cortex,
to severe erosion and presence of heavy endosteal cortical
residues and porosity of the inferior mandibular cortex,
unilaterally or bilaterally. Panoramic X-rays are cheap and
routinely performed in many patients, in contrast with DXA
which may be too expensive to be widely implemented in
population screening programs. Some authors concluded
that panoramic X-rays can help detect a high percentage of
postmenopausal women with undetected low BMD, as well
as undetected spinal fractures which may then be referred
for DXA [45–52]. Under the auspices of a European Union
Initiative (the OSTEODENT project), a special computer
software has been developed to facilitate early diagnosis of
osteoporosis by dental practitioners. The cost-eﬀectiveness
of the program has been documented [51–58]. Physicians
and dentists have a shared interest to identify patients at
risk of developing osteoporosis and periodontal disease.
Collaboration between these professionals to early diagnose
osteoporosis and osteopenia can lead to early osteoporosis
therapy and prevention of fractures.
4.Osteonecrosis ofthe Jaws (ONJ)
Osteonecrosis of the jaws (ONJ) was initially described as
anoralcomplicationresultingfromundergoingbisphospho-
nate therapy and is todate deﬁnedas the presenceof necrotic
bone anywhere in the oral cavity in a patient who is taking a
bisphosphonate, who has not received radiation to the head
and neck and in whom the necrotic area does not heal within
eight weeks after diagnosis after receiving proper care [7, 59,
60]. Patients with ONJ were classiﬁed in three stages, while
in 2009 a stage 0 was also proposed [61] and subsequently
adopted (Table 1)[ 59, 62]. Most reported cases of ONJ
have been associated with the intravenous administration
of zoledronic acid or pamidronate in patients with cancer-
related conditions, including bone metastases in the context
of solid tumors such as breast cancer, prostate cancer, and
lung cancer, and lytic lesions in the setting of multiple
myeloma [62–64]. ONJ also has been diagnosed, although
in a smaller number, in patients taking oral bisphosphonates
suchasalendronate,risedronate,ibandronateandclodronate
for the prevention and treatment of osteoporosis [65–67].
Various aetiopathogenetic paradigms have been proposed.
Table 2 brieﬂy summarizes those most plausible. Predispos-
ing factors that have been proposed to be associated with the
development of ONJ in patients under BP treatment include
dental extractions [68–70] ,u s eo fd e n t u r e s[ 68, 69], presence
of periodontal disease [69, 71], smoking [68, 69, 72],
diabetesmellitus[62],glucocorticoiduse[62]andprolonged
bisphosphonate therapy [69, 73]. Thus, reports of ONJ have4 Journal of Osteoporosis
implications for the dental care of patients with osteoporosis
[65]. It is important for dental practitioners to identify
patients who are taking a bisphosphonate. Due to the fact
that the majority of bisphosphonates are administred either
weekly or monthly, patients frequently forget to disclose
to dentists that they are taking the medication. Including
speciﬁc questions about osteoporosis and bisphosphonate
use in the dental history may facilitate the identiﬁcation of
those under BP treatment.
The ideal dental management protocol for patients
taking oral bisphosphonates has been a matter of debate.
It has been suggested that patients need be given a “drug
holiday” when surgical dental intervention that includes
bone manipulation is scheduled [91]. Existing evidence;
however, provides no scientiﬁc grounds to support the
theory that discontinuation of bisphosphonate therapy will
improve treatment outcomes [67, 92]. Therefore, before
discontinuing bisphosphonate therapy, dentists and physi-
cians must collaborate to determine the best way to manage
the treatment of each patient. Several health indicators,
including BMD, degree of risk of experiencing spine and
hip fractures and duration of bisphosphonate therapy would
need to be discussed in such a consultation. This consul-
tation also would help health care practitioners make a
decision about whether a drug holiday is acceptable for any
individual [8].
The risk of fracture following treatment over a period
of time and subsequent discontinuation of an oral bis-
phosphonate for patients with osteoporosis has not been
well established. The Fracture Intervention Trial Long-term
Extension (FLEX) evaluated the eﬀects of continuing or
stopping oral alendronate in postmenopausal women for up
to 10 years. Investigators found that BMD was maintained
and bone remodeling was suppressed with no detectable
increase in fracture risk [93]. In the group of women who
discontinued oral alendronate use after ﬁve years, the BMD
and bone remodeling were maintained at higher levels than
those obtained at baseline. The BMD and bone marker
changes suggested some residual eﬀect from 5 years of
alendronate treatment that is evident for at least 5 years after
discontinuation [93].
The association of hip fracture with high mortality
also is important, however the potential savings from hip
fracture prophylaxis may be overestimated by studies that
fail to consider diﬀerential risk, mortality, and long-term
followup [94]. Managing the care of a patient who has
ONJ and is taking a bisphosphonates is based mostly on
expert opinion [95]. Several strategies have been attempted,
including sequestrectomy, surgical local debridement and
periodontal ﬂap surgery, as well as less invasive procedures
like antibiotic therapy and mouthrinses [67, 78, 86, 95, 96].
Treatment outcomes vary from complete healing to partial
healing to no healing. Both practitioners and dentists must
keep in mind that the management of ONJ is diﬃcult
and no deﬁnite treatment exists to date. The osteonecrotic
process usually does not respond to routine therapy, and
more aggressive surgical manipulation of the area is not
recommended [97]. In those ONJ cases when there is clinical
evidence of active infection, conservative approaches such
as minor local debridement and systemic antibiotic therapy
are indicated. When there is trauma to the soft tissues
sharp bone edges should be eliminated. Routine oral hygiene
maintenance is indicated, and it can be complemented
with topical chlorhexidine rinses [59, 62, 67, 97]. Table 1
summarizes proposed interventions for patients receiving
BPs but also for those who developed ONJ.
When a patient taking oral bisphosphonate needs to
undergo a surgical procedure, Marx et al. suggested that the
patient discontinue BPs and undergo a serum C-telopeptide
test of type I collagen (CTX) prior to the procedure
[98]. CTX is used to measure bone resorption and detect
the fragments of collagen type I peptide released in the
circulatorysystemwhenosteoclastsresorbbone.Theauthors
recommended that when the CTX level is higher than 150
picogramspermilliliter,theriskofdevelopingONJfollowing
an invasive dental surgical procedure is diminished [98].
There are, however, no suﬃcient data to support the use of
CTX to predict the development of ONJ. An expert panel
recommended that using this test may not be an evidence-
based approach as a control group was missing in the initial
study [99]. Other authors also commented on the lack of
quality evidence with regard to the predictive value of CTX
[100] while a study with limited followup concluded that
serumCTXisnotavalidpreoperativetesttoaccuratelyassess
the level of risk of developing ONJ and is not indicated in the
oral surgery patient [101]. Because ONJ can be a devastating
complication of bisphosphonate therapy, a collaborative
eﬀort between dentists and physicians in deciding on the
patient’s dental treatment is recommended, because it can
minimize complications and adverse events. The reported
incidence of ONJ in patients taking oral bisphosphonates
is relatively low, which may be due to underreporting,
diﬀerent duration of therapy in countries that have adopted
bisphosphonates more recently and diﬀerent deﬁnitions
of ONJ [65, 66]. There are an estimated 0.7 cases per
100,000 patient-treatment years in the United States [74,
102]. However, some geographic variations in incidence are
being reported such as in Australia, where the number of
cases could be much higher [103]. Others believe that the
incidence of ONJ is low, considering the millions of patients
with osteoporosis who are taking oral bisphosphonates [67].
The development of new bisphosphonates may enhance the
safety of this medication. A recent clinical trial reported
the results of treating patients with osteoporosis with a
new formulation of bisphosphonate (Zoledronic acid 5mg,
Aclasta) [104]. Patients received an annual intravenous
infusion of 5milligrams of zoledronic acid for a period of
three years. The trial demonstrated a signiﬁcant reduction
of the risk of vertebral, hip and other fractures. Only two
cases of ONJ were detected; one in the treatment group,
and one in the placebo group [104]. It is not uncommon,
however, that drug adverse events emerge only after the drug
receives US Food and Drug Administration approval on a
postmarket basis and is widely adopted in everyday clinical
use [7].Journal of Osteoporosis 5
Table 1: Staging classiﬁcation of osteonecrosis of the jaws by bisphosphonates and treatment strategies (from Kyrgidis et al [59], modiﬁed
on the basis of current evidence).
Osteonecrosis of the jawsstaging Stage description Treatment strategies
Future risk category
Candidate patients to be enrolled
in bisphosphonate treatment,
patients who have enrolled to
bisphosphonate treatment for a
period shorter than 3 months
“Patient education” (inform patients about the
complication, its signs, and symptoms) [74]
“Maintain optimal oral hygiene” (biannual periodontal
scaling, restoration decayed teeth) [63, 74, 75]
“Provide root canal treatment as usual” [68, 69]
“Treat active oral infections, remove sites at high risk for
infection” (partially impacted wisdom teeth, nonrestorable
teeth, teeth with extensive periodontal dehiscence)
[60, 74, 75]
“Check for ill-ﬁtting dentures, retread if necessary” [68, 69]
Baseline dental evaluation (history taking, clinical
examination and panoramic radiographs) [68, 74, 75]
At-risk category
No apparent necrotic bone in
patients who have been treated
with either oral or IV
bisphosphonates
All of the above
“Prefer conservative dental treatment modalities over dental
extractions” (root canal treatment, periodontal scaling and
root planning) [68–70, 74]
Perform extractions and other surgery only when utterly
inevitable; in such cases use minimal bone manipulation
with appropriate local and systemic antibiotics
[68–70, 76]:
(i) Perform periodontal scaling 3 weeks prior
(ii) Prescribe amoxicillin 1gr t.i.d. 3 days prior
(iii) Reﬂect full thickness mucoperiosteal ﬂap, remove
teeth with minimal cortical trauma
(iv) Suture and prescribe amocicillin 1 gr t.i.d. for 17
days, chlorexidine 1% rinses t.i.d.
(vi) Remove sutures and discontinue chlorexidine
rinses 1 week postoperatively
(v) Prefer single tooth interventions
(vi) Followup to ensure healing
Stage 0
No clinical evidence of necrotic
bone, but non-speciﬁc clinical
ﬁndings and symptoms
All of the above
“Systemic management”, including use of pain medication
and antibiotics [62]
Stage 1 [77]
Exposed bone necrosis or small
oral ulceration without exposed
bone necrosis, but without
symptoms [77]
All of the above
“Oral antibacterial mouth rinse” (0.12% chlorhexidine
rinse, hydrogen peroxide)
“Impede denture use” [68, 69]
Discontinuation of bisphosphonate therapy until
osteonecrosis heals or underlying disease progresses is not
indicated but might be individually considered prior to
surgery [62, 78–80]
Clinical followup on quarterly basis [62]
Stage 2a [77]
Exposed bone necrosis or a small
oral ﬁstula without exposed bone
necrosis, but with symptoms
controlled with medical
treatment [77]
All of the above
Suggest computed tomography scans
Symptomatic treatment with oral antibiotics
(monotherapy or combination therapy with b-lactam,
tetracycline, macrolide, metronidazole, or clindamycin)
[74]
“Pain control” with non-steroid anti-inﬂammatory drugs6 Journal of Osteoporosis
Table 1: Continued.
Osteonecrosis of the jawsstaging Stage description Treatment strategies
Stage 2b [77]
Exposed bone necrosis or a small
oral ﬁstula without exposed bone
necrosis, but with symptoms not
controlled with medical
treatment [77]
All of the above
Supercial debridement to relieve soft tissue irritation
Stage 3 [77]
Jaw fractures, skin ﬁstula,
osteolysis extending to the
inferior border [77]
All of the above
Surgical debridement/resection for longer term palliation
of infection and pain under intravenous antibiotic
treatment
Use of doxycycline bone ﬂuorescence to discriminate
viable bone [81, 82]
Table 2: Most plausible aetipathogenetic paradigms for osteonecrosis of the jaws (ONJ).
Paradigm Synopsis Citations
Osteoclast-mediated
toxicity
Bisphosphonates suppress osteoclast-mediated bone remodeling. This suppression
results in “fatigue” of the alveolar bone, responsible for necrosis
[83–85]
Soft tissue toxicity The oral mucosa is initially involved. As the damage progresses, underlying alveolar bone
is also involved and the clinical presentation of ONJ becomes evident.
[79, 86]
Infection Increased bacterial adhesion to the bisphosphonate covered bone may be the cause for
ONJ development
[84, 87]
Impaired immune
homeostasis-macrophage
impaired function
Dendritic cells, macrophages, cytotoxic and helper T-lymphocytes are aﬀected by
bisphosphonates. Chemokines, like tumor necrosis factor-alpha, inteleukins IL-1a, IL-1b,
IL-6 and IL-8 are also impaired by bisphosphonates. Impaired immune response is
responsible for continued inﬂammation resulting in osteomyelitis. Impaired function of
macrophages due to RANKL inhibition is a key phenomenon in the defective topical
immune response
[79, 88–90]
5.SpeciﬁcOsteoporosis Treatment Agents
Denosumab is a human monoclonal IgG2 antibody that
binds selectively and with high aﬃnity to the receptor
activator of nuclear factor-κB ligand (RANKL) and pharma-
cologically mimics the eﬀect of osteoprotegerin on RANKL
[26, 27, 88] thereby blocking the binding of RANKL to the
receptor activator of nuclear factor-κB( R A N K ) .D e n o s u m a b
rapidly decreases bone turnover markers resulting in a
signiﬁcant increase in bone mineral density and reduction in
fracture risk [26, 27, 88]. Amgen’s denosumab was approved
under the brand name Prolia for osteoporosis in mid-2010
[105]. The safety and eﬃcacy of Prolia in the treatment
of postmenopausal osteoporosis was demonstrated in a
three-year, randomized, double-blind, placebo-controlled
trial of 7,808 postmenopausal women ages 60 to 91 years.
In the study, Prolia reduced the incidence of vertebral,
nonvertebral, and hip fractures in postmenopausal women
with osteoporosis [106]. Of note, in the latter study previous
bisphosphonate administration was a possible confounder;
however, the issue has been addressed by the authors [107].
Recently, denosumab was granted with FDA approval for
the prevention of skeletal-related events in patients with
bone metastases from solid tumors under the trade name
Xgeva [108]. While ONJ incidence with denosumab in
clinical trials has been negligible in those patients with
osteoporosis, in metastatic cancer patients ONJ has been
recorded as an adverse eﬀect [88, 109]. Importantly, it has
been suggested that since denosumab exhibits the advantage
of short clearance time when compared to bisphosphonates,
more feasible treatment and earlier healing of denosumab-
related ONJ when compared to bisphosphonate-related ONJ
could be anticipated [88].
Teriparatide, which consists of the N-terminal 34 amino
acids of parathyroid hormone, has been in clinical use
for the treatment of osteoporosis for almost a decade,
ever since clinical trials showed that among patients with
severe osteoporosis who were treated with teriparatide, the
relative risks of vertebral and nonvertebral fractures were
reduced by 65% and 53%, respectively [109, 110]. Unlike
bisphosphonates, the current ﬁrst-line agents for the pre-
vention of fractures, which act primarily by inhibiting bone
resorption, teriparatide increases bone density and strength
primarily by stimulating osteoblastic bone formation. Thus,
teriparatide stimulates bone remodeling, whereas bisphos-
phonatesdecreaseit[109].Arecentstudyreportedimproved
clinical outcomes, greater resolution of alveolar bone defects,
and accelerated osseous wound healing in a yearly followupJournal of Osteoporosis 7
in the oral cavity of patients with chronic periodontitis
who underwent periodontal surgery and received daily
injections of teriparatide or placebo, along with oral cal-
cium and vitamin D supplementation, for 6 weeks [110].
Teriparatide may oﬀer therapeutic potential for localized
bone defects in the jaw. Furthermore, teriparatide has been
reported to promote the spontaneous resolution of ONJ.
Despite the fact that the only three cases have been published
to date [111–114], given the FDA approval of teriparatide for
osteoporosis and the limited existing evidence with regard
to ONJ healing, it could be justiﬁed to prescribe teriparatide
to patients with bisphosphonate-treated osteoporosis who
already have ONJ.
6. Conclusions
The facial skeleton is a region of particular interest in
patients with osteoporosis. Firstly, inner ear pathophysiology
and manifestations may be related to calcium metabolism.
Evidence suggests that sex hormones convey changes to the
otoconia of the cochlea and the vestibule. Postmenopausal
osteoporosis is known to be associated with sex hormone
changes, and may be associated with benign paroxysmal
positional vertigo. Practitioners should be aware of these
symptoms and early refer their patients to ENT surgeons.
Secondly, although the relation between osteoporosis and
periodontal disease has not been quantiﬁed, maintenance of
optimal oral hygiene would likely be beneﬁcial for osteo-
porosis patients. Furthermore, panoramic X-rays widely
used in dentistry are of importance to early refer selected
patientsforDXAscreening.Goodknowledgeofosteoporosis
speciﬁc alterations in panoramic X-rays is a prerequisite
and dentists should be keen on referring these patients.
Thirdly,osteonecrosisofthejawsisoneofthemostdiscussed
complications resulting from bone mass preservation treat-
ment. Prevention and timely diagnosis of this complication
requires awareness and collaboration from both physicians
anddentists.Similartotheparadigmofbisphosphonatesand
ONJ, the broad introduction of denosumab and teriparatide
might bear skeletal-related complications but it might also
introduce new therapeutic potentials. Early recognition of
future complications and early exploitation of therapeutic
potentials mandate for a multidisciplinary approach.
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